Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System

Terumo Medical Corporation (TMC) has announced today the introduction of its AZUR™ Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo’s robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.

“The AZUR™ Vascular Plug represents a balance of properties – stability, accuracy, and reliable occlusion. This technology has unique advantages that truly make it a market first in embolotherapy, in line with Terumo’s ongoing efforts to deliver improved clinical outcomes and economic benefits,” said Chris Pearson, Executive Vice President, Commercial Operations, Terumo Interventional Systems.

The AZUR™ Vascular Plug comes in sizes to treat arterial anatomy ranging from 2.5mm to 8mm, with a short deployment length for increased precision. Features include a conformable nitinol braid that stays in place, even in tortuous anatomy. It also comes with a polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (PET) inner composite membrane to facilitate mechanical occlusion. Another key element in the Plug’s design is its advanced, predictable detachment mechanism that allows for immediate and reliable deployment with the push of a button. Consistent with Terumo’s existing Azur coil portfolio, this state-of-the-art detachment mechanism can allow for a full ability to reposition, while making the process much smoother than traditional twist-off detachment mechanisms.

The launch of AZUR™ Vascular Plug is complemented by the introduction of the PG Pro™ Peripheral Microcatheter, which is indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents. The PG Pro™ Microcatheter is designed specifically to deliver all three sizes of the Azur™ Vascular Plug. It comes in radial lengths up to 165 centimeters and a 1200 PSI rating for clearer fluoroscopic imaging. Both are currently only available in the United States.

“Together, these next-generation technologies allow physicians to treat larger, more difficult vessels through smaller delivery options. It is yet another way Terumo is providing the opportunity for operators to take advantage of the benefits of radial access for increasingly complex procedures, while enhancing therapeutic options in the peripheral vasculature with a microvascular plug. It is a welcome addition to our innovative, best-in-class portfolio,” added Michael Martinelli, MD, Chief Medical Officer, Terumo Medical Corporation.

This device should only be used by physicians who have undergone training in the use of the Azur system for embolization procedures as described by a representative from Terumo or a Terumo-authorized distributor. This device is intended for single use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”